Coca-Cola Company (KO) is in a very orderly advance, and its recent pullback gives a good opportunity to position yourself in this blue chip stock.
Note the turning fast-line of the stochastic, which should give a buy signal shortly.
Coca-Cola Company (KO) is in a very orderly advance, and its recent pullback gives a good opportunity to position yourself in this blue chip stock.
Note the turning fast-line of the stochastic, which should give a buy signal shortly.
It goes without saying that the investment strategy advocated here favors integrated oil companies, particularly those with a regional or product advantage. And with the aforementioned in mind, I'm reiterating my buy rating for Petroleo Brasileiro SA (PBR), also known as Petrobras, first recommended on April 22, 2009, at a price of $32.99. If you bought PBR in April, you're up an impressive 47%.
Petrobras remains on-track for 5% to 6% oil/natural gas production growth for FY2009 or about 2.54 million barrels of oil equivalent per day; longer-term, a roughly 7% to 7.5% average annual production increase is seen for 2010 to 2013.
The Canadian Oil Sands Trust (COSWF) is an open-ended investment trust that generates income from its 36.74% interest in the Syncrude Canada Ltd. joint venture, which is the world's largest producer of crude oil from oil sands and the largest single-source producer in Canada.
After falling from more than $50 in July 2008 to less than $15 in January 2009, this trust formed a base and then rallied from February to May before settling down for its next consolidation, a cup-and-handle formation.
After seven months of one of the strongest rallies in history, the stock market is showing signs of faltering. From here on out through the rest of 2009, I believe the advance will shift gears, and instead of recording new highs every month, the trend will tend to flatten.
And as we head into the heart of the fourth quarter, I wouldn't bet on the market making many more new highs this year.
So far, institutional investors (IIs) have not noticed that Hess Corp.'s (NYSE: HES) upstream operations (exploration and production) should benefit from high oil prices in the $80 per barrel range. But the argument here is that eventually they will, preferably starting in early 2010, which is why I'm reiterating my Buy rating for the company, first recommended on April 22, 2009 at a price of $50.41. Continue reading Despite stock's sluggishness, Hess remains a buy
It's a difficult call, but I'm Reiterating my Buy rating for Comcast Corp. (NASDAQ: CMCSA), first recommended on April 22, 2009 at a price of $14.05,
When you run across a stock with a 16% yield you at least have to check out the story. Prospect Capital Corp (NASDAQ: PSEC) is just such a company. Last week PSEC declared its 20th consecutive increased dividend.Continue reading Chasing Value: 16% yield -- Prospect Capital Corp
Now that there's credible evidence that the U.S. economy is recovering, U.S. gasoline demand may stabilize, helping refiners like Chevron Corp. (NYSE: CVX), hence I'm Reiterating my Buy rating for the company, first recommended on February 15, 2009 at a price of $66.18. Continue reading Chevron: Riding out the U.S. gasoline market's doldrums
Marathon Oil Corp. (NYSE: MRO) continues to inch along, 'totally un-spectacularly,' with performance weighed-down by the recession's impact on refined products.
Alternative fuel system company Fuel Systems Solutions Inc. (NASDAQ: FSYS) continues to progress. The company Thursday reported Q3 EPS of 77 cents versus the 43 cents First Call EPS estimate and the stock was up $8.82 to $42.63 at mid-day. I'm reiterating my Buy rating for the company, first recommended on August 17, 2009 at a price of $30.42, but wait for a pull-back following Thursday's surge. If bought FSYS in August, you're up about 40%."Gilead Sciences (NASDAQ: GILD) develops treatments for life-threatening diseases and specializes in drugs for HIV, the virus that causes AIDS," notes Hannah Choe.
The contributing editor to Personal Finance explains, "Already the market leader in HIV antivirals, Gilead is in the beginning stages of developing Quad, the first-ever, four-in-one AIDS pill.
"The manufacture of HIV drugs, which accounts for more than three-quarters of revenue, is Gilead's highest-grossing business. This segment has held up through the recession; in the second quarter product sales for the antiviral franchise grew 26% from a year ago to $1.41 billion.
Continue reading Gilead (GILD): New potential in 4-in-1 HIV drug
"We have very few buy recommendations currently; one exception is Franco-Nevada (Toronto: FNV.CA)," says resource expert Adrian Day.
In his The Global Analyst, the advisor explains, "Franco Nevada is one of our all-time favorites; it has top management, a solid balance sheet, and risk-averse business plan.
He continues, "The company previously merged with Newmont, and was reborn in a spin off nearly two years ago. Although the stock has nearly doubled since the IPO, it still represents good value.
Continue reading Franco Nevada (FNV): A core holding in gold
Continue reading Cramer on BloggingStocks: All I'm asking for is rigor
I'm reiterating my Buy rating for 3M Co. (NYSE: MMM), first recommended on April 20, 2009 at a price of $51.97. If you bought 3M in April, you're up an impressive 46%.
I'm Reiterating my Buy rating for Sunoco, Inc. (NYSE: SUN), first recommended on April 20, 2009 at a price of $26.58, but there are qualifiers, so close attention is warranted. If you bought SUN in April, you're up about 19%. Continue reading Sunoco: Modest progress amid tepid gasoline sales
Find out why more people track their portfolios on AOL Money & Finance then anywhere else.
Other Weblogs Inc. Network blogs you might be interested in: